Trends in robotic surgery in Korean gynecology
Article information
Abstract
Objective
The objective of this study is to discover the trends of robotic surgery in gynecology since the introduction of robotic surgery platforms in Korea.
Methods
Data for the use of robotic surgery in gynecologic diseases were collected from the 14 hospitals that perform most of the robotic gynecologic surgeries in Korea. Records of robotic surgeries from between 2006 and 2019 were selected (n=12,405), and data including diagnoses, approach methods, and names of surgical procedures were obtained. Statistical analysis was performed, including a trend test.
Results
Overall, robotic surgery in gynecology showed an increasing trend (Spearman correlation coefficient r=0.99, <i>P</i><0.001). The common cases in which robotic surgery was used for benign diseases were uterine leiomyoma, adnexal tumors, and adenomyosis, which accounted for 68%, 17%, and 9% of benign cases, respectively. Common malignant diseases were cervical cancer, endometrial cancer, and ovarian cancer, accounting for 55%, 35%, and 5% of malignant cases, respectively. This increasing trend was significantly evident in uterine leiomyoma, both single-site and multiport approaches.
Conclusion
Since robotic surgical platforms were introduced in Korea, the number of gynecologic robotic surgeries has grown rapidly. Considering these data, the use of robotic surgery is expected to grow continuously for both benign and malignant gynecological diseases. A large amount of minimal invasive surgeries are expected to be replaced with robotic surgeries.
INTRODUCTION
Since the introduction of the robotic surgical platform in the field of minimally invasive surgeries (MIS), robotic surgery has become a global trend. By the year 2018, 4,986 da Vinci® surgical systems (Intuitive Surgical, Sunnyvale, CA, USA) have been installed worldwide [1]. In Korea, 96 da Vinci® surgical systems have been installed since the introduction of the first robotic surgical platform in 2006, and in 2019, these systems were available in 61 hospitals.
Robotic surgery is making up an increasing portion of MIS. Robotic surgery has the same advantages as MIS, including less postoperative pain, shorter hospital stays, and shorter recovery times. It also has the added advantages of view magnification using 3D imaging, tremor filters, and other specialized instruments [2]. Based on these advantages, the scope of robotic surgery is expected to expand. Robotic surgery has led to an implementation of the spread of MIS, particularly in frail patients [3] and for highly complex interventions [4,5]. In practice, laparoscopic surgery and robotic surgery are both performed by selecting a surgeon. However, as robotic surgery techniques develop, patients’ demand for it increases. In light of this, it is necessary to conduct statistical analyses on robotic surgeries performed in Korean gynecology.
It has been more than a decade since the first robotic surgical platform was adopted in Korean gynecology. Our outcome of interest was to analyze the annual change of robot utilization in both benign and malignant diseases, to compare them to each other, and to analyze the trend in the utilization of robotic systems, including the number of ports used to perform surgery in a given disease.
We analyzed trends in the field of gynecologic robotic surgery in terms of operation volumes, diagnoses, and approach methods. This analysis will help us understand and predict future changes in Korean gynecologic robotic surgery.
MATERIALS AND METHODS
1. Data source
By the year 2019, a total of 80 da Vinci® surgical systems (regardless of version) were installed and used by gynecology surgeons in 63 tertiary medical centers throughout Korea. Of these, 14 medical centers voluntarily participated to provide data of patients who underwent gynecologic robotic surger y between the years 20 06 and 2019 (n=12,405). The collected data was analyzed retrospectively.
Cases that were included involved the diagnosis of female genital organs using da Vinci® S, Si, X, Xi, or SP by gynecologic oncology or general gynecologic specialists in the department of obstetrics and gynecology within each medical center. Patients’ ages were recorded at the time of surgery. Robotic surgeries using a single-site approach includes procedures in which all of the robotic arms and ports for the assistant instrument were utilized via single incision. Robotic surgeries with multiple ports included those with additional robotic arm utilization or that used a single-site approach with an additional port for a surgical instrument manipulated by an assistant. The latter were considered multiport robotic surgeries.
Diagnoses were first categorized as benign or malignant diseases and then subcategorized according to the diagnosis code of the Health Insurance Review and Assessment Service. Benign diseases include uterine leiomyoma, adnexal tumor, adenomyosis, pelvic organ prolapse, cervical intraepithelial neoplasia, endometrial hyperplasia, endometrial polyp, cervical mass, and vaginal intraepithelial neoplasia. Malignant diseases include cervical cancer, endometrial cancer, gestational trophoblastic neoplasia, ovarian cancer, peritoneal cancer, tubal cancer, uterine cancer, vaginal cancer, and vulvar cancer. Tumors that were diagnosed as ovarian borderline tumors or stromal tumors of unknown malignant potential were categorized as malignant diseases.
2. Statistical analysis
SPSS version 26.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to analyze the collected data. The Spearman correlation test was conducted to analyze the relationship between categorical variables. Spearman correlation analysis was conducted with ρ indicating the crude Spearman coefficient. A P-value of less than 0.05 was considered statistically significant.
RESULTS
The volume of overall robotic surgeries in benign gynecology and gynecologic oncology showed an increasing trend between 2006 and 2019 (Spearman correlation coefficient r=0.99, P<0.001) (Fig. 1A). Robotic surgery began in 2006 using a multiport approach. Data on single-site surgeries have been collected since 2009, because single-site surgery began after the introduction of the Si system. In 2006, 18 cases of robotic surgery were performed. In 2019, 13 years later, the volume increased to 3,860. The rate of yearly increase has been faster in the last five years, increasing by 58.6% in 2015, 54.3% in 2016, 36.9% in 2017, 57.6% in 2018, and 40% in 2019 compared to each previous year in this study. The volume of overall robotic surgeries showed the biggest on-year growth in 2015 in the last 5 years.
Trends of robotic surgery in gynecology and gynecologic oncology by year. (A) Overall trend of robotic surgery. (B) Trend by approach, multiport versus single-site. (C) Distribution in age. (D) Trend of robotic surgery in benign and malignant diseases.
Single-site surgeries began to increase in 2014 after new da Vinci Si system was introduced and have been on the rise every year since (Fig. 1B). In 2019, 987 cases of singlesite robotic surgery were performed in Korea. The volume of single-site surgeries increased by 118.4% in 2015, 94.7% in 2016, 77.6% in 2017, 31.5% in 2018, and 14.2% in 2019 compared to each previous year. Multiport surgeries were performed in 18 cases in 2006, the first year that robotic surgery was introduced in Korea, and they increased by 46.7% in 2015, 42.3% in 2016, 20.3% in 2017, 73.4% in 2018, and 51.8% in 2019 compared to each previous year. Both single-site and multiport surgeries show a growing trend in statistical analysis (r=0.90 and r=0.99, respectively, P<0.001). Patients who underwent robotic surgery were primarily in aged 30–60. There was no difference in age distribution between all gynecological surgeries (Fig. 1C).
The analysis of robotic surgery was performed according to the type of disease. Benign diseases were a primary indication for gynecologic robotic surgery and showed an increasing trend over the study period (r=0.98, P<0.001) (Fig. 1D). In 2019, 3,380 cases of robotic surgery were performed for benign diseases. The volume of robotic surgery for benign disease has increased significantly since 2015. The proportion of benign surgeries increased by 76.0% in 2017, 81.2% in 2018, and 87.6% in 2019 compared to each previous year. The rates of increase were 58.7% in 2016, 46.7% in 2017, 68.5% in 2018, and 51.0% in 2019 compared to each previous year. For malignant diseases, the volume of robotic surgeries showed a slow but increasing trend (r=0.99, P<0.001).
Uterine leiomyoma was the most common indication for gynecologic robotic surgery in benign diseases, accounting for 68% of all benign cases (Fig. 2A). Adnexal tumors and adenomyosis followed, accounting for 17% and 9% of benign cases, respectively. In malignant diseases, robotic surgery was conducted mainly in cervical cancer and endometrial cancer, accounting for 92% of all cases (47% and 45%, respectively) (Fig. 2B). Ovarian cancer accounted for 5% of malignant cases.
Distribution of indication for gynecologic robotic surgeries. (A) Distribution in benign diseases. (B) Distribution in malignant diseases. POP, pelvic organ prolapse; CIN, cervical intraepithelial neoplasia; EM, endometrial; VAIN, vaginal intraepithelial neoplasia; BOT, borderline ovarian tumor; GY, gynecologic; STUMP, smooth muscle tumor of uncertain malignant potential; GTN, gestational trophoblastic neoplasia.
In the view of the platform system, both single-site and multiport surgeries increased for benign diseases (Fig. 3A). Robotic surgery for main indications increased steadily in both benign and malignant diseases. In malignant diseases, the number of robotic surgeries on both platforms continued to increase until 2018 but decreased in 2019, especially for cervical cancer. In particular, single-site surgeries showed a greater decrease (Fig. 3B). Overall, robotic surgeries showed a trend in which uterine leiomyoma and endometrial cancer were the main indications for benign and malignant diseases, respectively (Fig. 4).
Annual change of robotic surgeries in gynecology and gynecologic oncology by approach. (A) Annual change in benign diseases. (B) Annual change in malignant diseases.
Annual change of robotic surgeries in gynecology and gynecologic oncology by diagnosis. (A) Annual change in benign diseases. (B) Annual change in malignant diseases. CIN, cervical intraepithelial neoplasia; EM, endometrial; POP, pelvic organ prolapse; VAIN, vaginal intraepithelial neoplasia; BOT, borderline ovarian tumor; GY, gynecologic; STUMP, smooth muscle tumor of uncertain malignant potential; GTN, gestational trophoblastic neoplasia.
DISCUSSION
In the USA, Food and Drug Administration clinical clearances were obtained for gynecologic surgical procedures in April 2005. Gynecology was the second-largest surgical specialty that used robotic surgery in the USA in 2018, with a procedure volume of approximately 265,000 cases in 2018, compared with 252,000 in 2017 and 246,000 in 2016 [1]. Also in 2018, gynecologic robotic surgery in the USA only grew 5.2% compared to the previous year, while outside the USA, the field of robotic surgery grew rapidly, driven by urologic surgery, general surgery, and gynecologic oncologic procedures. Over the past 5 years, robotic surgeries have increased by 20% every year worldwide [1,6]. In Korea, the number of gynecologic procedures increased by 57.6% in 2018 and 40% in 2019 compared to each previous year in this study. This trend is much faster than the global trend. Needs of minimal scar on surgeries has increased, causing the volume of MIS to grow steadily. The demand for robotic platforms, for which young people are quickly adapting, is rapidly increasing for benign diseases. In particular, robotic surgery for uterine leiomyoma has shown a rapid rise. In myomectomy, the advantage of robotic surgery over laparoscopy is that sutures are more accessible and easier to experience. In Korea, the number of patients treated for uterine myoma in women in reproductive age (aged 20–50) is increasing every year. Ministry of Health and Welfare reported that the number of uterine myoma patients increased 21% in 2009 compared by 2004 [7] and number of patients and medical cost was steadily increased between 2009 and 2013 [8]. As the age of pregnancy has increased, the number of uterine leiomyoma patients who need surgery to preserve their fertility has also increased, in turn affecting the frequency of robotic surgery for uterine leiomyoma.
In the past 5 years, robotic surgery showed significant growth in gynecologic oncology. Endometrial and cervical cancer with MIS contributed to this growth. However, the reduction of robotic surgery for cervical cancer in 2019 is noticeable (Fig. 4B). As the result of the “Laparoscopic Approach to Carcinoma of the Cervix (LACC) trial,” concerns about oncological outcomes led to the need for more data collection and analysis, resulting in a decrease in robotic surgery for cervical cancer [9]. The results of the LACC trial caused controversy in that the oncological outcome of MIS was lower than that of laparotomic surgery. The controversy is that the recurrence rate was lower than that in other studies, and the follow-up period of the study was short, so the proficiency of the surgeons performing the MIS has been questioned [10-12]. For this reason, there has been an effort to identify and select patients who may have lower risks with MIS. In Europe, a robotic surgery group is currently conducting a “Robotic-assisted Approach to Cervical Cancer (RACC) trial” to compare the oncologic outcomes of open surgery and robotic surgery in early cervical cancer [13]. To clarify the role of MIS in treating cervical cancer, it is necessary to wait for the results of other studies that are currently ongoing.
Despite all of this, the utility of robotic surgery for endometrial cancer is notable, as many studies have reported the efficacy of robotic surgery in endometrial cancer already. A randomized controlled trial conducted in Finland compared the surgical outcomes of laparoscopy with robotic surgery in endometrial cancer [14]. The trial’s result showed that the outcomes were similar between the groups, but robotic surgery improved patients’ quality of life, with benefits noted up to 12 weeks after surgery [15]. Bernardini et al. reported that robotic surgery would be a safe and effective option in the surgical treatment of endometrial cancer, especially in obese women [16-18].
Robotic surgery is more beneficial for less experienced surgeons because it allows faster and more accurate training compared to laparoscopic surgery [19,20]. The benefits of robotic surgery are further reinforced by the application of improved instruments and docking methods whenever a new robotic system is developed. These contributed to the rapid installation of robotic systems in hospitals. In Korea, the major obstacle to the expansion of robotic surgery may be a concern about price [21]. Patients with private insurance are less burdened with medical costs, and robotic surgery is more accessible to them. Reducing the cost of robotic surgery will improve accessibility for all patients.
Given the advantages of MIS and robotic surgery, Korean surgeons and patients have a high preference for it. As fast as the volume of robotic surgery is growing, the MIS platform is replacing conventional laparoscopy with robotic surgery. Nevertheless, conventional laparoscopy has its own advantages, so the choice of robotic or laparoscopic surgery should be based on proper indications before an operation is conducted.
When robotic surgery was first introduced, laparoscopic surgery had already become a potent platform for MIS, and some devalued the utility of robots. Now, however, robotic surgery is thought to have become alternative form of MIS equivalent to laparoscopic surgery.
Notes
Conflict of interest
No potential conflict of interest relevant to this article was reported.